Actionable news
All posts from Actionable news
Actionable news in VBLT: VASCULAR BIOGENICS Ltd,

VBL Therapeutics Announces Significant Improvement Of 12 Month Overall Survival With VB-111 Compared To Pooled Data From Four Avastin(R) Studies At The Annual Meeting Of The Society For Neuro-Oncology


TEL AVIV, Israel, Nov. 19, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced the presentation of new data on its lead oncology product VB-111, a first-in-class, targeted, anti-angiogenic gene-therapy agent with applicability for multiple solid tumor indications, at the 20th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), being held in San Antonio, Texas, showing significant improvement of 12 month overall survival (OS) with VB-111 in recurrent Glioblastoma...